PTC Therapeutics (NASDAQ:PTCT – Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.42, FiscalAI reports. The business had revenue of $272.55 million during the quarter, compared to the consensus estimate of $218.80 million. PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. The business’s revenue for the quarter was up 43.5% on a year-over-year basis. During the same quarter last year, the firm earned $10.04 earnings per share.
Here are the key takeaways from PTC Therapeutics’ conference call:
- Record quarter with $273M total revenue and $226M net product revenue; management raised 2026 product revenue guidance to $750M–$850M and total revenue to $1.08B–$1.18B.
- Sephience launch accelerating—Q1 Sephience revenue was $125M (36% QoQ), U.S. starts averaging ~140/month, >90% of U.S. PKU centers have prescribed, and commercial roll‑out is planned in up to 30 countries by year‑end with payers covering >2/3 of the U.S. population.
- Positive 24‑month PIVOT‑HD interim results for votoplam: the 10 mg dose showed a ~52% slowing of disease progression vs a matched natural history cohort in Stage 2 and a favorable safety profile, supporting the Novartis‑led phase III INVEST‑HD (≈770 pts) now enrolling.
- Vatiquinone path forward agreed with FDA: an open‑label, natural‑history‑controlled 24‑month study (≈120 patients, age 7–21, primary mFARS) will be initiated to support NDA resubmission, which management says increases probability of success but requires additional data collection.
- Strong liquidity with $1.89B in cash, cash equivalents and marketable securities as of March 31, 2026, which management says supports ongoing R&D, the Sephience launch, and selective accretive business development.
PTC Therapeutics Price Performance
Shares of PTC Therapeutics stock traded up $9.20 during trading on Friday, reaching $73.69. 5,836,355 shares of the stock traded hands, compared to its average volume of 1,252,004. The business has a fifty day simple moving average of $67.69 and a two-hundred day simple moving average of $72.07. The company has a market capitalization of $6.11 billion, a price-to-earnings ratio of 9.52 and a beta of 0.53. PTC Therapeutics has a 52-week low of $43.17 and a 52-week high of $87.50.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on PTCT
Trending Headlines about PTC Therapeutics
Here are the key news stories impacting PTC Therapeutics this week:
- Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
- Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
- Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
- Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
- Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Insiders Place Their Bets
In other PTC Therapeutics news, Director Stephanie Okey sold 15,167 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $70.00, for a total transaction of $1,061,690.00. Following the transaction, the director directly owned 8,000 shares in the company, valued at $560,000. This trade represents a 65.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Mark Elliott Boulding sold 3,081 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $213,698.16. Following the transaction, the vice president directly owned 108,231 shares in the company, valued at $7,506,902.16. The trade was a 2.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 126,492 shares of company stock worth $8,634,621. 5.50% of the stock is owned by company insiders.
Hedge Funds Weigh In On PTC Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in PTCT. Invesco Ltd. lifted its position in PTC Therapeutics by 38.7% during the fourth quarter. Invesco Ltd. now owns 434,285 shares of the biopharmaceutical company’s stock valued at $32,988,000 after acquiring an additional 121,228 shares during the last quarter. Summit Global Investments purchased a new position in PTC Therapeutics in the fourth quarter worth $242,000. State of Tennessee Department of Treasury acquired a new position in shares of PTC Therapeutics during the fourth quarter worth $2,465,000. Mackenzie Financial Corp lifted its holdings in shares of PTC Therapeutics by 17.4% during the 4th quarter. Mackenzie Financial Corp now owns 236,909 shares of the biopharmaceutical company’s stock valued at $18,015,000 after purchasing an additional 35,117 shares during the last quarter. Finally, Empowered Funds LLC lifted its holdings in shares of PTC Therapeutics by 473.0% during the 4th quarter. Empowered Funds LLC now owns 250,412 shares of the biopharmaceutical company’s stock valued at $19,021,000 after purchasing an additional 206,707 shares during the last quarter.
About PTC Therapeutics
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
See Also
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
